psilocybin – Page 4

Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers

mycolabadmin

This large international study of over 8,700 people found that adults who microdose psychedelics report taking small doses for health and wellness reasons. Among people with anxiety or depression, microdosers showed lower symptom levels than non-microdosers. Most microdosers used psilocybin and combined it with other substances like Lion’s Mane mushrooms or niacin, practices they refer to as stacking.

Global species diversity and distribution of the psychedelic fungal genus Panaeolus

mycolabadmin

This study is a comprehensive catalog of 77 Panaeolus mushroom species worldwide, of which 20 are known to be hallucinogenic and contain psilocybin. Researchers found that these mushrooms are most commonly documented in Asia, South America, and Europe, but many regions have little to no research data. The review highlights significant gaps in our knowledge about where these species exist and which ones truly contain psychoactive compounds, information that is crucial as these fungi become legal in more countries for medical use.

Current situation regarding psychedelics and magic mushroom in Korea

mycolabadmin

This article reviews the current status of psychedelic mushrooms and their potential medical uses in Korea. Several wild mushroom species containing psilocybin have been identified in Korea and can cause hallucinations and other nervous system effects lasting a few hours. While psychedelics show promise for treating depression and anxiety, Korea currently classifies them as controlled substances, and only approved clinical trials can be conducted with government permission.

Body mass index (BMI) does not predict responses to psilocybin

mycolabadmin

Researchers investigated whether a person’s body weight affects how they respond to psilocybin-assisted therapy. Analyzing 77 participants across three studies, they found that BMI did not predict how intensely people experienced the drug or how much their mental health improved afterward. This surprising finding suggests that everyone might benefit from the same fixed dose of psilocybin rather than doses adjusted to body weight, making therapy simpler and more cost-effective to deliver at scale.

Attitudes toward psychedelics and psychedelic-assisted psychotherapy among Australian mental healthcare providers

mycolabadmin

Australian doctors and mental health professionals have positive views about using psychedelics like psilocybin and MDMA to treat depression and trauma, which were recently approved by regulators. However, many still have safety concerns and gaps in their knowledge, particularly psychiatrists. Most doctors learn about psychedelics from podcasts and websites rather than formal training. The study recommends that professional organizations provide better education to prepare healthcare workers for this new treatment approach.

Knowledge, perceptions, and use of psychedelics for mental health among autistic adults: An online survey

mycolabadmin

This survey studied how autistic adults feel about using psychedelics like psilocybin mushrooms for mental health. Nearly 70% of participants had tried psychedelics before and most found them helpful for anxiety and depression. Many participants were interested in trying them or participating in research, though legal and practical barriers stood in the way. The study suggests that psychedelics could be a promising treatment option for autistic people with mental health challenges.

The Afterglow Inventory (AGI): Validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics

mycolabadmin

Researchers created a new questionnaire called the Afterglow Inventory to measure the positive effects people experience in the days and weeks after using psychedelics like psilocybin and LSD. These ‘afterglow’ effects include improved mood, feelings of spiritual connection, increased creativity, and better relationships. The study with over 1,300 participants showed the questionnaire works well at measuring these effects, which could help researchers better understand how psychedelics might help treat depression and other conditions.

An investigation of acute physiological and psychological moderators of psychedelic-induced personality change among healthy volunteers

mycolabadmin

This study examined how a single high dose of psilocybin affects personality in healthy people. Participants who took psilocybin showed decreased anxiety-related personality traits (neuroticism) one month later. The effects were stronger in people who found the experience personally meaningful or who experienced more anxiety during the psychedelic state, suggesting that the intensity and meaning of the experience matters for lasting personality changes.

We need to talk about shrooms

mycolabadmin

The article discusses how psychedelic mushrooms have transformed from being seen as dangerous drugs in the 1960s to being studied as potential psychiatric treatments today. While research shows promise for treating depression, trauma, and addiction, the author warns against oversimplified narratives that ignore important context about how these experiences work and potential risks. The piece calls for careful, balanced discussion about psychedelics that considers both benefits and concerns.

A Review of the Food and Drug Administration Pipeline and Proposed California Legislation on Medicinal Psychedelics

mycolabadmin

Psychedelic compounds like psilocybin and ketamine show promise in treating serious mental health conditions including PTSD and depression. The FDA carefully evaluates these drugs through multi-phase clinical trials to ensure they are safe and effective. While California has proposed making psychedelics more widely available through legislation, the FDA’s thorough approval process provides important protections by identifying potential risks and ensuring proper medical oversight.

Research Topic: psilocybin